Stock AnalizArcutis Biotherapeutics, Inc. ARQT
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Arcutis Biotherapeutics, Inc. (ARQT) is a healthcare company listed in the US with a market value of about $3.6B. In the twelve months to September 30, 2026 it had revenue of $509M and net income of $30M, a net margin of 5.9%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a P/E of 134.6, a price to free cash flow of 59.9, a 5-year average ROIC of -41%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 26% below the current price.
Score: 1.6 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $509M | $376M | $197M | $60M | $4M | $0 | $0 | — | — |
| Net income | $30M | -$16M | -$140M | -$262M | -$311M | -$206M | -$136M | -$42M | -$19M |
| Free cash flow | $60M | -$6M | -$112M | -$247M | -$258M | -$176M | -$113M | -$43M | -$14M |
| EPS (diluted) | $0.21 | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 | $-3.80 | $-22.78 | $-15.53 |
| Net margin | 5.9% | -4.3% | -71.2% | -439.8% | -8449.8% | — | — | — | — |
| ROIC | — | -3.2% | -37.8% | -64.7% | -57.8% | -43.5% | -39.2% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $40.38, 43% above the current price; targets range from $34.00 to $48.00; the consensus rating is “Strong buy”; expected EPS is $0.33 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Arcutis Biotherapeutics’s P/E ratio?
About 134.6, based on the last twelve months of diluted earnings per share (forward P/E about 35.4).
Is Arcutis Biotherapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 26% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Arcutis Biotherapeutics pay a dividend?
Not currently.
Is Arcutis Biotherapeutics a good stock to buy?
We do not give buy or sell advice. Arcutis Biotherapeutics scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.